106 related articles for article (PubMed ID: 24361045)
1. Monoclonal antibodies for clinical trials of Duchenne muscular dystrophy therapy.
Le TL; Nguyen TM; Morris GE
Neuromuscul Disord; 2014 Mar; 24(3):195-200. PubMed ID: 24361045
[TBL] [Abstract][Full Text] [Related]
2. Monitoring duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies.
Morris G; Man Nt; Sewry CA
Methods Mol Biol; 2011; 709():39-61. PubMed ID: 21194020
[TBL] [Abstract][Full Text] [Related]
3. Characterization of genetic deletions in Becker muscular dystrophy using monoclonal antibodies against a deletion-prone region of dystrophin.
Le Thiet Thanh ; Nguyen Thi Man ; Hori S; Sewry CA; Dubowitz V; Morris GE
Am J Med Genet; 1995 Aug; 58(2):177-86. PubMed ID: 8533812
[TBL] [Abstract][Full Text] [Related]
4. Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy.
Nguyen TM; Morris GE
Am J Hum Genet; 1993 Jun; 52(6):1057-66. PubMed ID: 7684887
[TBL] [Abstract][Full Text] [Related]
5. A case of Becker muscular dystrophy resulting from the skipping of four contiguous exons (71-74) of the dystrophin gene during mRNA maturation.
Patria SY; Alimsardjono H; Nishio H; Takeshima Y; Nakamura H; Matsuo M
Proc Assoc Am Physicians; 1996 Jul; 108(4):308-14. PubMed ID: 8863344
[TBL] [Abstract][Full Text] [Related]
6. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
7. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
8. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB
Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies against the muscle-specific N-terminus of dystrophin: characterization of dystrophin in a muscular dystrophy patient with a frameshift deletion of exons 3-7.
Le TT; Nguyen TM; Love DR; Helliwell TR; Davies KE; Morris GE
Am J Hum Genet; 1993 Jul; 53(1):131-9. PubMed ID: 8317478
[TBL] [Abstract][Full Text] [Related]
10. Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform.
Lim BC; Lee S; Shin JY; Kim JI; Hwang H; Kim KJ; Hwang YS; Seo JS; Chae JH
J Med Genet; 2011 Nov; 48(11):731-6. PubMed ID: 21969337
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
12. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
13. Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of duchenne muscular dystrophy by immunostaining and western blot.
Kodippili K; Vince L; Shin JH; Yue Y; Morris GE; McIntosh MA; Duan D
PLoS One; 2014; 9(2):e88280. PubMed ID: 24516626
[TBL] [Abstract][Full Text] [Related]
14. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin.
Thanh LT; Nguyen TM; Helliwell TR; Morris GE
Am J Hum Genet; 1995 Mar; 56(3):725-31. PubMed ID: 7887428
[TBL] [Abstract][Full Text] [Related]
15. ELISA quantitation of dystrophin for the diagnosis of Duchenne and Becker muscular dystrophies.
Byers TJ; Neumann PE; Beggs AH; Kunkel LM
Neurology; 1992 Mar; 42(3 Pt 1):570-6. PubMed ID: 1549217
[TBL] [Abstract][Full Text] [Related]
16. An epitope structure for the C-terminal domain of dystrophin and utrophin.
Morris GE; Sedgwick SG; Ellis JM; Pereboev A; Chamberlain JS; Nguyen thi Man
Biochemistry; 1998 Aug; 37(31):11117-27. PubMed ID: 9693008
[TBL] [Abstract][Full Text] [Related]
17. Deletion mutations in the dystrophin gene of Saudi patients with Duchenne and Becker muscular dystrophy.
Al-Jumah M; Majumdar R; Al-Rajeh S; Chaves-Carballo E; Salih MM; Awada A; Al-Shahwan S; Al-Uthaim S
Saudi Med J; 2002 Dec; 23(12):1478-82. PubMed ID: 12518196
[TBL] [Abstract][Full Text] [Related]
18. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
Ferrer A; Wells KE; Wells DJ
Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
[TBL] [Abstract][Full Text] [Related]
19. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
Madden HR; Fletcher S; Davis MR; Wilton SD
Hum Mutat; 2009 Jan; 30(1):22-8. PubMed ID: 18570328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
